GANTANOL
LOE ApproachingNDAORALSUSPENSION
Approved
Jul 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTANOL is an oral suspension small-molecule drug approved by Roche in 1965. The generic name and mechanism of action are not currently documented in available records. This legacy product represents a mature asset in Roche's historical portfolio.
LOE Approaching
This legacy product approaching loss of exclusivity is likely supported by a minimal, maintenance-focused team with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GANTANOL offers limited career growth given zero linked job openings and LOE-approaching lifecycle stage. This role is suitable for professionals seeking maintenance-focused, established-product experience rather than launch or growth opportunities.
Brand ManagerField Sales
Worked on GANTANOL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.